awmsg logo



epoetin theta (Eporatio®)


Reference No. 592

Publication date:
18/11/2010


Appraisal information

epoetin theta (Eporatio®) solution for injection


Company: TEVA UK Ltd
BNF category: Nutrition and blood
NMG meeting date: 15/09/2010
AWMSG meeting date: 13/10/2010
   
   
Submission Type: Full Submission
Status: Partially superseded
Advice No: 1610
Ministerial ratification: 17/11/2010

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE PARTIALLY SUPERSEDED BY NICE GUIDANCE (TA323) NICE GUIDANCE ISSUED NOVEMBER 2014 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Epoetin theta (Eporatio®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with symptomatic anaemia associated with chronic renal failure only. AWMSG is of the opinion that epoetin theta (Eporatio®) is not suitable for shared care within NHS Wales for the above indication. Epoetin theta (Eporatio®) should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance. Epoetin theta (Eporatio®) is not recommended for use within NHS Wales for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. The case for clinical effectiveness of epoetin theta (Eporatio®) has not been proven in this indication.
Final Appraisal Recommendation (FAR)
Download